Excitingly, dual MEK–CDK4/6 inhibition induced an anti-tumor immune response, which sensitized MPNSTs to immune checkpoint inhibitor therapy using anti-PD-L1 (programmed death-ligand 1) therapy, with about 10% of mice showing cure with long-term treatment. The gene discussed is MAP2K7; the disease is neoplasm.